Zhong-Zhe Lin
National Taiwan University(TW)National Taiwan University Hospital(TW)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Microtubule and mitosis dynamics, Lung Cancer Treatments and Mutations, Cancer-related Molecular Pathways, Lung Cancer Research Studies
Most-Cited Works
- → First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma(2019)244 cited
- → Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma(2007)91 cited
- → A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma(2019)58 cited
- → The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma(2008)45 cited
- → Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors(2010)29 cited
- → Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma(2012)29 cited
- → High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy(2008)26 cited
- → Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)(2017)26 cited
- → Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma(2021)19 cited
- → Phase II Multicentered Study of Low-Dose Everolimus plus Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin as First-Line Treatment for Patients with Advanced Gastric Cancer(2014)19 cited